These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 23625177)

  • 21. Immune Parameters That Distinguish Multiple Sclerosis Patients from Patients with Other Neurological Disorders at Presentation.
    Mouzaki A; Rodi M; Dimisianos N; Emmanuil A; Kalavrizioti D; Lagoudaki R; Grigoriadis NC; Papathanasopoulos P
    PLoS One; 2015; 10(8):e0135434. PubMed ID: 26317430
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cerebrospinal fluid and serum levels and intrathecal production of active matrix metalloproteinase-9 (MMP-9) as markers of disease activity in patients with multiple sclerosis.
    Fainardi E; Castellazzi M; Bellini T; Manfrinato MC; Baldi E; Casetta I; Paolino E; Granieri E; Dallocchio F
    Mult Scler; 2006 Jun; 12(3):294-301. PubMed ID: 16764342
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Soluble HLA class I molecules/CD8 ligation trigger apoptosis of CD8+ cells by Fas/Fas-ligand interaction.
    Puppo F; Contini P; Ghio M; Indiveri F
    ScientificWorldJournal; 2002 Feb; 2():421-3. PubMed ID: 12806026
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Soluble class 1 antigens (sHLA) in CSF and serum of patients with HIV infection.
    Alvarez-Cermeño JC; Casado C; Villar LM; Ferreira A; Varela JM; Dominguez M; Bootello A; Najera R; Gonzalez-Porque P
    Acta Neurol Scand; 1990 Jul; 82(1):14-6. PubMed ID: 2239130
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Saliva soluble HLA as a potential marker of response to interferon-beta 1a in multiple sclerosis: a preliminary study.
    Minagar A; Adamashvili I; Kelley RE; Gonzalez-Toledo E; McLarty J; Smith SJ
    J Neuroinflammation; 2007 Jul; 4():16. PubMed ID: 17601341
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cytokines and Soluble HLA-G Levels in the Acute and Recovery Phases of Arbovirus-Infected Brazilian Patients Exhibiting Neurological Complications.
    Almeida RS; Ferreira MLB; Sonon P; Cordeiro MT; Sadissou I; Diniz GTN; Militão-Albuquerque MFP; Franca RFO; Donadi EA; Lucena-Silva N
    Front Immunol; 2021; 12():582935. PubMed ID: 33776990
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical relevance and functional implications for human leucocyte antigen-g expression in non-small-cell lung cancer.
    Lin A; Zhu CC; Chen HX; Chen BF; Zhang X; Zhang JG; Wang Q; Zhou WJ; Hu W; Yang HH; Xu HH; Yan WH
    J Cell Mol Med; 2010 Sep; 14(9):2318-29. PubMed ID: 19602033
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Detection of soluble HLA-G molecules in plasma and amniotic fluid.
    Rebmann V; Pfeiffer K; Pässler M; Ferrone S; Maier S; Weiss E; Grosse-Wilde H
    Tissue Antigens; 1999 Jan; 53(1):14-22. PubMed ID: 10082427
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chitinase 3-like proteins as diagnostic and prognostic biomarkers of multiple sclerosis.
    Hinsinger G; Galéotti N; Nabholz N; Urbach S; Rigau V; Demattei C; Lehmann S; Camu W; Labauge P; Castelnovo G; Brassat D; Loussouarn D; Salou M; Laplaud D; Casez O; Bockaert J; Marin P; Thouvenot E
    Mult Scler; 2015 Sep; 21(10):1251-61. PubMed ID: 25698171
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Kappa Free Light Chains, Soluble Interleukin-2 Receptor, and Interleukin-6 Help Explore Patients Presenting With Brain White Matter Hyperintensities.
    Levraut M; Landes C; Mondot L; Cohen M; Bresch S; Brglez V; Seitz-Polski B; Lebrun-Frenay C
    Front Immunol; 2022; 13():864133. PubMed ID: 35401550
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human neuroblastoma cells trigger an immunosuppressive program in monocytes by stimulating soluble HLA-G release.
    Morandi F; Levreri I; Bocca P; Galleni B; Raffaghello L; Ferrone S; Prigione I; Pistoia V
    Cancer Res; 2007 Jul; 67(13):6433-41. PubMed ID: 17616704
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Soluble human leukocyte antigen-G and interleukin-10 levels in plasma of psoriatic patients: preliminary study on a possible correlation between generalized immune status, treatments and disease.
    Borghi A; Fogli E; Stignani M; Melchiorri L; Altieri E; Baricordi O; Rizzo R; Virgili A
    Arch Dermatol Res; 2008 Nov; 300(10):551-9. PubMed ID: 18797896
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic relevance of the C-X-C motif chemokine ligand 13 and interleukin-8 in predicting the transition from clinically isolated syndrome to multiple sclerosis.
    Klíčová K; Mareš J; Sobek O; Rous Z; Rous M; Raška M; Hartung HP
    Eur J Neurosci; 2024 Jun; 59(11):2955-2966. PubMed ID: 38453679
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cerebrospinal fluid IL-12p40, CXCL13 and IL-8 as a combinatorial biomarker of active intrathecal inflammation.
    Bielekova B; Komori M; Xu Q; Reich DS; Wu T
    PLoS One; 2012; 7(11):e48370. PubMed ID: 23226202
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Soluble-HLA-E: A follow up biomarker in Takayasu arteritis, independent of HLA-E genotype.
    Goel R; Kabeerdoss J; Mohan H; Danda S; Jayaseelan V; Kumar TS; Jude J; Bacon P; Joseph G; Danda D
    Int J Rheum Dis; 2018 Feb; 21(2):532-540. PubMed ID: 28425192
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The predictive value of CSF multiple assay in multiple sclerosis: A single center experience.
    De Fino C; Lucchini M; Lucchetti D; Nociti V; Losavio FA; Bianco A; Colella F; Ricciardi-Tenore C; Sgambato A; Mirabella M
    Mult Scler Relat Disord; 2019 Oct; 35():176-181. PubMed ID: 31394405
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Soluble HLA-G and HLA-E Levels in Bone Marrow Plasma Samples Are Related to Disease Stage in Neuroblastoma Patients.
    Morandi F; Pozzi S; Carlini B; Amoroso L; Pistoia V; Corrias MV
    J Immunol Res; 2016; 2016():7465741. PubMed ID: 27610393
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Investigating Serum sHLA-G Cooperation With MRI Activity and Disease-Modifying Treatment Outcome in Relapsing-Remitting Multiple Sclerosis.
    Amoriello R; Rizzo R; Mariottini A; Bortolotti D; Gentili V; Bonechi E; Aldinucci A; Carnasciali A; Peruzzi B; Repice AM; Massacesi L; Fainardi E; Ballerini C
    Front Neurol; 2022; 13():872396. PubMed ID: 35693002
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HLA-G and HLA-E in patients with juvenile idiopathic arthritis.
    Prigione I; Penco F; Martini A; Gattorno M; Pistoia V; Morandi F
    Rheumatology (Oxford); 2011 May; 50(5):966-72. PubMed ID: 21186170
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Soluble HLA-G in rheumatoid arthritis.
    Verbruggen LA; Rebmann V; Demanet C; De Cock S; Grosse-Wilde H
    Hum Immunol; 2006 Aug; 67(8):561-7. PubMed ID: 16916651
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.